Overview
Raloxifene is classified as a PCT (post-cycle therapy) and ancillary compound. Selective estrogen receptor modulator with tissue-specific activity.
With a half-life of ~1.2 days (28 hours), Raloxifene supports less frequent dosing schedules. Taken orally, it has a bioavailability of approximately 2% via its primary route.
Low oral bioavailability (~2%) due to extensive first-pass metabolism. Half-life approximately 28 hours. One-compartment model.
Mechanism of Action
Raloxifene's pharmacological activity involves the following key pathways:
Selective Estrogen Receptor Modulation
Raloxifene acts as a selective estrogen receptor modulator, functioning as an antagonist in breast tissue while having varying effects in other estrogen-sensitive tissues.
Hypothalamic Feedback
By blocking estrogen receptors in the hypothalamus, Raloxifene interrupts negative feedback, which can stimulate endogenous gonadotropin production.
Dosing Protocols
The following protocols represent commonly observed dosing patterns. These are observational summaries, not recommendations.
Dose
60 mg/day
Route
Oral
Frequency
Every other day
Duration
4-8 weeks
Dose
120 mg/day
Route
Oral
Frequency
Every other day
Duration
4-8 weeks
Frequently Asked Questions
What is raloxifene and how does it work?
Raloxifene is a second-generation selective estrogen receptor modulator (SERM) that acts as an estrogen antagonist in breast tissue while functioning as an estrogen agonist in bone. Its benzothiophene ring binds estrogen receptors with affinity similar to estradiol, but its large side-chain alters receptor conformation in a tissue-specific manner – blocking estrogen-driven gene activation in breast tissue while preserving beneficial estrogenic activity in bone and lipid metabolism.
How is raloxifene used for gynecomastia?
Raloxifene is commonly used for the management and reversal of gynecomastia due to its high selectivity for breast tissue estrogen receptors. Clinical data has observed a greater than 50% reduction in breast tissue in 86–93% of treated individuals. The typical protocol involves 60 mg daily for 3–9 months, though some protocols use up to 120 mg per day for more pronounced cases.
What is the half-life of raloxifene?
Raloxifene has a single-dose elimination half-life of approximately 27.7 hours. At steady state with 60 mg daily dosing, the half-life averages 32.5 hours (range 15.8–86.6 hours). The extended half-life is attributed to extensive enterohepatic recirculation and high plasma protein binding, which allows for convenient once-daily dosing.
How does raloxifene compare to tamoxifen?
Raloxifene demonstrates greater selectivity for breast tissue estrogen receptors than tamoxifen. Clinical observations report higher response rates for gynecomastia reduction with raloxifene (86%) compared to tamoxifen (41%). Raloxifene also has a lower incidence of visual side effects and less impact on IGF-1 levels. However, tamoxifen stimulates LH and FSH more strongly, making it the more common choice as a primary PCT compound for testosterone recovery.
What are the common side effects of raloxifene?
The most commonly reported side effects include hot flashes (occurring in approximately 1 in 10 users, most prevalent during the first 6 months), leg cramps (approximately 1 in 14 users), mild fluid retention, and joint discomfort. Unlike tamoxifen, raloxifene is not commonly associated with visual disturbances. It is metabolized exclusively by glucuronidation rather than the cytochrome P450 system, resulting in fewer drug interactions.
Does raloxifene affect testosterone levels in men?
Raloxifene has been observed to disinhibit the hypothalamic-pituitary-gonadal axis, resulting in increased total testosterone levels in men. However, due to a simultaneous increase in sex hormone-binding globulin (SHBG), free testosterone levels often remain unchanged. This is why raloxifene is not typically used as a primary post-cycle therapy compound for testosterone recovery – its value lies primarily in its breast tissue selectivity for gynecomastia management.